Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
8-K
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
8 Apr 24
8-K
Entry into a Material Definitive Agreement
29 Feb 24
10-K
2023 FY
Annual report
21 Feb 24
8-K
Ionis reports fourth quarter and full year 2023 financial results
21 Feb 24
8-K
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
22 Jan 24
8-K
Other Events
21 Dec 23
8-K
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
18 Dec 23
8-K
Ionis announces the appointment of Michael Yang to Board of Directors
14 Dec 23
S-3ASR
Automatic shelf registration
24 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Ionis reports third quarter 2023 financial results
2 Nov 23
8-K
Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer’s disease and Huntington’s disease
27 Sep 23
8-K
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome
26 Sep 23
8-K
Other Events
23 Aug 23
8-K
Other Events
21 Aug 23
S-8
Registration of securities for employees
10 Aug 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Ionis reports second quarter 2023 financial results
9 Aug 23
8-K
Termination of a Material Definitive Agreement
4 Aug 23
8-K
Entry into a Material Definitive Agreement
3 Aug 23
8-K
Eplontersen continued to show improvement in ATTRv-PN through 85 weeks
10 Jul 23
8-K
Ionis prices private placement of convertible senior notes
12 Jun 23
8-K
Ionis announces proposed private placement
6 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
5 Jun 23
10-Q
2023 Q1
Quarterly report
3 May 23
8-K
Ionis reports first quarter 2023 financial results
3 May 23
8-K
FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS
25 Apr 23
8-K
Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
24 Apr 23
ARS
2022 FY
Annual report to shareholders
20 Apr 23
DEFA14A
Additional proxy soliciting materials
20 Apr 23
DEF 14A
Definitive proxy
20 Apr 23
8-K
Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN
27 Mar 23
10-K
2022 FY
Annual report
22 Feb 23
8-K
Ionis reports fourth quarter and full year 2022 financial results
22 Feb 23
8-K
Entry into a Material Definitive Agreement
9 Jan 23
8-K
Entry into a Material Definitive Agreement
14 Nov 22
10-Q
2022 Q3
Quarterly report
9 Nov 22
Latest ownership filings
144
Notice of proposed sale of securities
3 May 24
4
Joseph Baroldi
17 Apr 24
4
Brian Birchler
17 Apr 24
144
Notice of proposed sale of securities
16 Apr 24
144
Notice of proposed sale of securities
16 Apr 24
4
Kyle Jenne
13 Mar 24
3
Kyle Jenne
13 Mar 24
4
Eric Swayze
4 Mar 24
4
Brett P Monia
4 Mar 24
4
Richard S Geary
4 Mar 24
4
Brian Birchler
4 Mar 24
4
C FRANK BENNETT
4 Mar 24
144/A
Notice of proposed sale of securities (amended)
20 Feb 24
4
Brett P Monia
16 Feb 24
144
Notice of proposed sale of securities
16 Feb 24
SC 13G
T. Rowe Price Investment Management, Inc.
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BB BIOTECH AG
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Eric Swayze
2 Feb 24
4
Eugene Schneider
2 Feb 24
4
PATRICK R. O'NEIL
2 Feb 24
4
Brett P Monia
2 Feb 24
4
ELIZABETH L HOUGEN
2 Feb 24
4
Richard S Geary
2 Feb 24
4
Onaiza Cadoret-Manier
2 Feb 24
4
C FRANK BENNETT
2 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
144/A
Notice of proposed sale of securities (amended)
1 Feb 24
144/A
Notice of proposed sale of securities (amended)
1 Feb 24
144
Notice of proposed sale of securities
31 Jan 24
4
Brett P Monia
29 Jan 24
4
PATRICK R. O'NEIL
29 Jan 24